
Solid Biosciences Inc.: shareholders and insiders
Price
$6.25
November 20, 2026Market cap $944M
What Ploutos Investor adds for Solid Biosciences
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Oct 26, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$2.7M
7 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $2.6M by 7 people
- 2025: no buys, sold $117.1K by 4 people
- 2026: no buys, sold $2.6M by 7 people
- Oct 19, 2026Gabriel BrooksChief Medical OfficerKind10b5-1
- Oct 18, 2026Gabriel BrooksChief Medical OfficerKind10b5-1
- Oct 2, 2026Ian F SmithDirectorKind
- Jul 2, 2026Ian F SmithDirectorKind
- Feb 18, 2026Kevin TanCFO & TreasurerKind10b5-1
- Feb 18, 2026Gabriel BrooksChief Medical OfficerKind10b5-1
- Feb 18, 2026David T HowtonChief Operating OfficerKind10b5-1
- Feb 18, 2026Paul HerzichChief Technology OfficerKind10b5-1
- Feb 18, 2026Ilan GanotKind10b5-1
- Feb 18, 2026Jessie HanrahanChief Regulatory OfficerKind10b5-1
- Feb 18, 2026Alexander CumboPresident and CEOKind10b5-1
- Feb 4, 2026Paul HerzichChief Technology OfficerKind10b5-1
- Feb 4, 2026Jessie HanrahanChief Regulatory OfficerKind10b5-1
- Feb 4, 2026Gabriel BrooksChief Medical OfficerKind10b5-1
- Feb 4, 2026Kevin TanCFO & TreasurerKind10b5-1
- Feb 4, 2026Ilan GanotKind10b5-1
- Feb 4, 2026Alexander CumboPresident and CEOKind10b5-1
- Feb 4, 2026David T HowtonChief Operating OfficerKind10b5-1
- Feb 2, 2026Paul HerzichChief Technology OfficerKind10b5-1
- Feb 2, 2026David T HowtonChief Operating OfficerKind10b5-1
- Feb 2, 2026Gabriel BrooksChief Medical OfficerKind10b5-1
- Feb 2, 2026Jessie HanrahanChief Regulatory OfficerKind10b5-1
- Feb 2, 2026Alexander CumboPresident and CEOKind10b5-1
- Feb 2, 2026Kevin TanCFO & TreasurerKind10b5-1
- Jan 28, 2026Ilan GanotKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | Gabriel BrooksChief Medical Officer | 10b5-1 | 4,374 | $5.62 | $24.6K | Form 4 |
| Oct 18, 2026 | Gabriel BrooksChief Medical Officer | 10b5-1 | 9,750 | – | – | Form 4 |
| Oct 2, 2026 | Ian F SmithDirector | 3,440 | – | – | Form 4 | |
| Jul 2, 2026 | Ian F SmithDirector | 3,440 | – | – | Form 4 | |
| Feb 18, 2026 | Kevin TanCFO & Treasurer | 10b5-1 | 5,404 | $5.82 | $31.5K | Form 4 |
| Feb 18, 2026 | Gabriel BrooksChief Medical Officer | 10b5-1 | 0 | $5.82 | – | Form 4 |
| Feb 18, 2026 | David T HowtonChief Operating Officer | 10b5-1 | 7,469 | $5.82 | $43.5K | Form 4 |
| Feb 18, 2026 | Paul HerzichChief Technology Officer | 10b5-1 | 3,616 | $5.82 | $21.0K | Form 4 |
| Feb 18, 2026 | Ilan Ganot | 10b5-1 | 2,658 | $5.82 | $15.5K | Form 4 |
| Feb 18, 2026 | Jessie HanrahanChief Regulatory Officer | 10b5-1 | 4,134 | $5.82 | $24.1K | Form 4 |
| Feb 18, 2026 | Alexander CumboPresident and CEO | 10b5-1 | 16.6K | $5.82 | $96.9K | Form 4 |
| Feb 4, 2026 | Paul HerzichChief Technology Officer | 10b5-1 | 10.9K | $6.44 | $70.2K | Form 4 |
| Feb 4, 2026 | Jessie HanrahanChief Regulatory Officer | 10b5-1 | 12.3K | $6.44 | $79.5K | Form 4 |
| Feb 4, 2026 | Gabriel BrooksChief Medical Officer | 10b5-1 | 12.6K | $6.44 | $81.2K | Form 4 |
| Feb 4, 2026 | Kevin TanCFO & Treasurer | 10b5-1 | 14.8K | $6.44 | $95.2K | Form 4 |
| Feb 4, 2026 | Ilan Ganot | 10b5-1 | 7,205 | $6.44 | $46.4K | Form 4 |
| Feb 4, 2026 | Alexander CumboPresident and CEO | 10b5-1 | 48.9K | $6.44 | $315.0K | Form 4 |
| Feb 4, 2026 | David T HowtonChief Operating Officer | 10b5-1 | 18.9K | $6.44 | $121.7K | Form 4 |
| Feb 2, 2026 | Paul HerzichChief Technology Officer | 10b5-1 | 26.3K | $6.44 | $169.1K | Form 4 |
| Feb 2, 2026 | David T HowtonChief Operating Officer | 10b5-1 | 37.8K | $6.44 | $243.2K | Form 4 |
| Feb 2, 2026 | Gabriel BrooksChief Medical Officer | 10b5-1 | 28.3K | $6.44 | $182.5K | Form 4 |
| Feb 2, 2026 | Jessie HanrahanChief Regulatory Officer | 10b5-1 | 26.5K | $6.44 | $170.9K | Form 4 |
| Feb 2, 2026 | Alexander CumboPresident and CEO | 10b5-1 | 80.3K | $6.44 | $516.9K | Form 4 |
| Feb 2, 2026 | Kevin TanCFO & Treasurer | 10b5-1 | 26.8K | $6.44 | $172.8K | Form 4 |
| Jan 28, 2026 | Ilan Ganot | 10b5-1 | 191 | $6.59 | $1.3K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 11, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by SLDB's officers and directors from 2018 up to November 21, 2025, 8 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 3 more, back to 2018
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Perceptive Advisors LLCwith 3 more personsShare of class11.2%
- RA Capital Management, L.P.with 3 more personsShare of class10.8%
- Invus Public Equities, L.P.with 7 more personsShare of class9.99%
- BCLS SB Investco, LPwith 5 more personsShare of class8.80%
- FMRwith 1 more personShare of class7.00%
- BlackRock, Inc.Share of class6.50%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Perceptive Advisors LLCwith 3 more persons | 11.2% | 12.05M | Aug 14, 20263 filings since Feb 21, 2025 | 13D/A | |
| RA Capital Management, L.P.with 3 more persons | 10.8% | 12.04M | Nov 6, 20266 filings since Feb 21, 2025 | 13D/A | |
| Invus Public Equities, L.P.with 7 more persons | 9.99% | 10.07M | May 5, 20263 filings since Feb 12, 2025 | 13G/A | |
| BCLS SB Investco, LPwith 5 more persons | 8.80% | 8.60M | Mar 10, 20262 filings since Feb 21, 2025 | 13D/A | |
| FMRwith 1 more person | 7.00% | 6.88M | Aug 6, 2026 | 13G | |
| BlackRock, Inc. | 6.50% | 6.42M | Jul 30, 20263 filings since Jul 17, 2025 | 13G |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter-26%
- Point72 (Cohen)In the quarter-78%
- Millennium Mgmt (Englander)In the quarter
- D.E. ShawIn the quarter-48%
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter+1.6%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 2.10M | -26% | $15M | 0.01% |
| Point72 (Cohen) | 100.5K | -78% | $700.0K | 0.00% |
| Millennium Mgmt (Englander) | 237.6K | $1.7M | 0.00% | |
| D.E. Shaw | 116.0K | -48% | $800.0K | 0.00% |
| Renaissance Technologies | – | – | 0.00% | |
| AQR Capital | 139.3K | +1.6% | $1.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.14% of its shares outstanding were held short, -3.3% since the report before.
- Shares held short
- 12.30M
- 8.14%
- Since the report before12.73M on Sep 30, 2026
- -3.3%
- 8.5
- 1.44M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 86%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 37.8K
- Nov 15, 2023: Shares held short 35.7K
- Nov 30, 2023: Shares held short 217.2K
- Dec 15, 2023: Shares held short 203.4K
- Dec 29, 2023: Shares held short 247.8K
- Jan 12, 2024: Shares held short 384.0K
- Jan 31, 2024: Shares held short 428.3K
- Feb 15, 2024: Shares held short 607.3K
- Feb 29, 2024: Shares held short 633.6K
- Mar 15, 2024: Shares held short 614.9K
- Mar 28, 2024: Shares held short 920.9K
- Apr 15, 2024: Shares held short 1.05M
- Apr 30, 2024: Shares held short 913.5K
- May 15, 2024: Shares held short 929.2K
- May 31, 2024: Shares held short 840.2K
- Jun 14, 2024: Shares held short 904.1K
- Jun 28, 2024: Shares held short 3.05M
- Jul 15, 2024: Shares held short 1.66M
- Jul 31, 2024: Shares held short 1.60M
- Aug 15, 2024: Shares held short 1.73M
- Aug 30, 2024: Shares held short 1.69M
- Sep 13, 2024: Shares held short 1.66M
- Sep 30, 2024: Shares held short 1.73M
- Oct 15, 2024: Shares held short 1.77M
- Oct 31, 2024: Shares held short 1.48M
- Nov 15, 2024: Shares held short 1.52M
- Nov 29, 2024: Shares held short 1.55M
- Dec 13, 2024: Shares held short 1.76M
- Dec 31, 2024: Shares held short 2.06M
- Jan 15, 2025: Shares held short 2.33M
- Jan 31, 2025: Shares held short 2.65M
- Feb 14, 2025: Shares held short 2.95M
- Feb 28, 2025: Shares held short 7.32M
- Mar 14, 2025: Shares held short 7.84M
- Mar 31, 2025: Shares held short 8.62M
- Apr 15, 2025: Shares held short 8.06M
- Apr 30, 2025: Shares held short 7.09M
- May 15, 2025: Shares held short 9.05M
- May 30, 2025: Shares held short 8.35M
- Jun 13, 2025: Shares held short 8.08M
- Jun 30, 2025: Shares held short 10.14M
- Jul 15, 2025: Shares held short 10.23M
- Jul 31, 2025: Shares held short 10.11M
- Aug 15, 2025: Shares held short 9.78M
- Aug 29, 2025: Shares held short 9.85M
- Sep 15, 2025: Shares held short 9.94M
- Sep 30, 2025: Shares held short 10.18M
- Oct 15, 2025: Shares held short 9.57M
- Oct 31, 2025: Shares held short 8.92M
- Nov 14, 2025: Shares held short 9.55M
- Nov 28, 2025: Shares held short 10.54M
- Dec 15, 2025: Shares held short 9.94M
- Dec 31, 2025: Shares held short 10.03M
- Jan 15, 2026: Shares held short 8.60M
- Jan 30, 2026: Shares held short 8.66M
- Feb 13, 2026: Shares held short 9.43M
- Feb 27, 2026: Shares held short 9.54M
- Mar 13, 2026: Shares held short 9.75M
- Mar 31, 2026: Shares held short 10.05M
- Apr 15, 2026: Shares held short 9.44M
- Apr 30, 2026: Shares held short 8.81M
- May 15, 2026: Shares held short 9.10M
- May 29, 2026: Shares held short 9.60M
- Jun 15, 2026: Shares held short 11.61M
- Jun 30, 2026: Shares held short 18.27M
- Jul 15, 2026: Shares held short 17.67M
- Jul 31, 2026: Shares held short 17.04M
- Aug 14, 2026: Shares held short 16.62M
- Aug 31, 2026: Shares held short 16.38M
- Sep 15, 2026: Shares held short 17.11M
- Sep 30, 2026: Shares held short 12.73M
- Oct 15, 2026: Shares held short 12.30M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading69.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 69.2% of the shares in the reported trades were short sales, against 65.9% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 69.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 65.9%
- Change
- +3.3 pts
- Short sales a dayon average, of 421.8K shares
- 291.9K
- More than atof 3,666 US-listed companies, same days
- 97%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 26.2%
- Oct 15, 2026: Short sales 76.7%
- Oct 16, 2026: Short sales 78.7%
- Oct 19, 2026: Short sales 64.4%
- Oct 20, 2026: Short sales 70%
- Oct 21, 2026: Short sales 75.9%
- Oct 22, 2026: Short sales 51.5%
- Oct 23, 2026: Short sales 68.6%
- Oct 26, 2026: Short sales 65.7%
- Oct 27, 2026: Short sales 89%
- Oct 28, 2026: Short sales 86.1%
- Oct 29, 2026: Short sales 79.1%
- Oct 30, 2026: Short sales 81.5%
- Nov 2, 2026: Short sales 63.7%
- Nov 3, 2026: Short sales 63.5%
- Nov 4, 2026: Short sales 73.7%
- Nov 5, 2026: Short sales 59.1%
- Nov 6, 2026: Short sales 67.7%
- Nov 9, 2026: Short sales 69.6%
- Nov 10, 2026: Short sales 80.9%
- Nov 11, 2026: Short sales 77%
- Nov 12, 2026: Short sales 65.9%
- Nov 13, 2026: Short sales 66.5%
- Nov 16, 2026: Short sales 73.6%
- Nov 17, 2026: Short sales 57.1%
- Nov 18, 2026: Short sales 62.9%
- Nov 19, 2026: Short sales 73.1%
- Nov 20, 2026: Short sales 71.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Joseph EdelmanDirector,TenPercentOwnerDirectly–
- Perceptive Xontogeny Venture Fund, LPDirector,TenPercentOwnerDirectly–
- BCLS SB Investco, LPTenPercentOwnerDirectly–
- Robert AtchinsonTenPercentOwnerDirectly–
- RA Capital Nexus Fund, L.P.Director,TenPercentOwnerDirectly–
- Alexander CumboPresident and CEODirectly235.4K
- Ian F SmithDirectorDirectly141.6K
- Ilan GanotDirectorDirectly95.4K
- David T HowtonChief Operating OfficerDirectly105.1K
- Kevin TanCFO & TreasurerDirectly99.4K
- Gabriel BrooksChief Medical OfficerDirectly97.2K
- Jessie HanrahanChief Regulatory OfficerDirectly74.3K
- Paul HerzichChief Technology OfficerDirectly72.6K
- Jennifer MarloweCSODirectly6,998
- Clare KahnDirectorDirectly2,960
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Joseph EdelmanDirector,TenPercentOwner | – | 11.83M | Feb 19, 2025 | Form 4 |
| Perceptive Xontogeny Venture Fund, LPDirector,TenPercentOwner | – | 6.83M | Jan 11, 2024 | Form 4 |
| BCLS SB Investco, LPTenPercentOwner | – | 5.03M | Feb 19, 2025 | Form 4 |
| Robert AtchinsonTenPercentOwner | – | 4.25M | Feb 18, 2025 | Form 4 |
| RA Capital Nexus Fund, L.P.Director,TenPercentOwner | – | 4.19M | Jan 11, 2024 | Form 4 |
| Alexander CumboPresident and CEO | 235.4K | – | Feb 18, 2026 | Form 4 |
| Ian F SmithDirector | 141.6K | – | Oct 2, 2026 | Form 4 |
| Ilan GanotDirector | 95.4K | 27.5K | Feb 18, 2026 | Form 4 |
| David T HowtonChief Operating Officer | 105.1K | – | Feb 18, 2026 | Form 4 |
| Kevin TanCFO & Treasurer | 99.4K | – | Feb 18, 2026 | Form 4 |
| Gabriel BrooksChief Medical Officer | 97.2K | – | Oct 19, 2026 | Form 4 |
| Jessie HanrahanChief Regulatory Officer | 74.3K | – | Feb 18, 2026 | Form 4 |
| Paul HerzichChief Technology Officer | 72.6K | – | Feb 18, 2026 | Form 4 |
| Jennifer MarloweCSO | 6,998 | – | Dec 4, 2023 | Form 4 |
| Clare KahnDirector | 2,960 | – | Mar 11, 2025 | Form 4 |
A lower bound: it counts only the 15 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.24%
- IWCiShares Micro-Cap ETFWeight in the fund0.17%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.14%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.07%
- IBBiShares Biotechnology ETFWeight in the fund0.06%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.03%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.02%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.02%
19 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 129
- Q4 2025: Managers 131
- Q1 2026: Managers 150
- Q2 2026: Managers 156
Institutional investors by quarter
The fund managers holding SLDB, quarter by quarter, from Q1 2018 to Q2 2025, 30 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 156 managers held 115M shares, worth $1.1B. During the quarter 41 opened a position, 28 closed one, 53 added and 37 trimmed.
The largest holders, Q2 2026
- Ra Capital ManagementIn the quarter+29%
- Perceptive AdvisorsIn the quarter
- Bain Capital Life Sciences InvestorsIn the quarter
- SirenIn the quarter
- BlackRockIn the quarter+40%
- FMRIn the quarter+91%
- Armistice CapitalIn the quarter+34%
- State StreetIn the quarter+271%
- Jupiter TopcoIn the quarter
- Vanguard Capital ManagementIn the quarter+50%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Ra Capital Management | 12.04M | +29% | $120M |
| Perceptive Advisors | 11.91M | $119M | |
| Bain Capital Life Sciences Investors | 9.81M | $98M | |
| Siren | 7.69M | $77M | |
| BlackRock | 6.93M | +40% | $69M |
| FMR | 6.88M | +91% | $69M |
| Armistice Capital | 4.28M | +34% | $43M |
| State Street | 4.18M | +271% | $42M |
| Jupiter Topco | 4.04M | $40M | |
| Vanguard Capital Management | 4.01M | +50% | $40M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Solid Biosciences's filings show?
Who buys and sells is one part of Solid Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have SLDB's insiders bought or sold?
From Jun 11, 2026 to Oct 26, 2026 Solid Biosciences's insiders bought 0 and sold $24.6K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold SLDB?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $15M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.